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Abstract
Long protocol of Gonadotropin-Releasing Hormone-analougue (GnRH-a) can result in 
the formation of ovarian cyst by the transient initial stimulatory effect which increases the 
levels of both follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These cysts 
require surgical drainage or result in poor ovarian response. Ovarian cyst formation can be 
prevented by taking oral contraceptives (OCs) which suppress LH and FSH after initiation of 
GnRH-a therapy. This study was designed to investigate ovarian cyst formation during therapy 
with depot formulation of GnRH-a and also the effect of taking (OCs) before starting the 
treatment with depot formulation of GnRH-a, on the formation of ovarian cyst, implantation 
and pregnancy rate in assisted reproductive tecnique (ART) cycles. Fifty four infertile women 
who were candidate for ART, underwent two treatment protocols in a prospective randomized 
trial: (a) OC+HMG+diphereline and (b) HMG+diphereline. In group (a) patients were 
pretreated with OC for 14 days starting from the first day of mensturation and on the day 14 
received 3.75 mg IM depot diphereline. Patients in group (b) received 3.75 mg diphereline 
by intramuscular injection on the second day of menstruation. Sonography was performed on 
the first day of menstruation and also 7 and 14 days after diphereline injection. Ovarian cyst 
incidence, gonadotropin consumption, follicular growth, implantation rate and pregnancy in 
the two groups were studied. No ovarian cyst with diameter over 26 mm was developed with 
depot formulation of GnRH-a in any of the two groups (a and b). There was no significant 
difference between the two groups in the follicular growth (9.2±2.1 and 9.4±2.9), number of 
oocyte (5.0±2.8 and 5.4±5.7), implantation rate (0.02 ±0.08 and 0.03±0.10) and pregnancy 
rate (0.09 and 0.11 ). We divided the patients into two groups based on their ages: (20-34) and 
(≥35). It showed no significant difference in the gonadotropin consumption , mean number of 
follicles and mean number of embryos in groups (a and b) based on their ages. No ovarian cyst 
developed with depot formulation of GnRH-a. So, in women with a history of ovarian cyst 
formation in previous cycles depot form of GnRH-a may be considered. Pretreatment with OCs 
during therapy with depot formulation of GnRH-a and gonadotropin didn’t increase the number 
of oocyte, implantation rate and pregnancy.
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Introduction
Using of GnRH-analogue before ovarian 
stimulation with gonadotropins in ART cycles 
has resulted in an increasing number of oocytes 
obtained, higher fertilization rates, better embryo 
quality, higher pregnancy and live birth rates. 
(1-3). It has also shown that long protocol GnRH-
a can improve the ART results in comparison 
with ultrashort or short protocols (4) and when 
the long protocol is used, initiation of GnRH-
a administration in the early follicular phase 
results in less profound pituitary suppression, 
greater number of oocytes collected and possibly 
higher pregnancy rates compared with initiation 
of GnRH-a administration in the midluteal 
phase (5-6). In some patients, long protocol of 
GnRH-a will result in the formation of ovarian 
cysts that require surgical drainage or prolonged 
exposure to GnRH-a (7). Baseline ovarian cysts 
have a negative impact on the quality of ovarian 
hyperstimulation procedure (8).
These functional ovarian cysts are formed 
by the transient initial stimulatory effect of the 
GnRH-a. 
This drug increases the levels of both FSH 
and LH and stimulates primordial follicles to 
grow but due to rapid pituitary suppression, 
continued follicular development and ovulation 
does not occur and consequently follicular cysts 
are formed. Pretreatment with OCs will suppress 
of LH and FSH after initiation of GnRH-a 
therapy and can be effective in the prevention of 
ovarian cyst formation (7).
In this study, we investigated the incidence of 
ovarian cyst formation during depot formulation 
of GnRH-a administration and the effect of 
pretreatment with an oral contraceptive on 
ovarian cyst formation during GnRH-a therapy 
as well as its effect on subsequent implantation 
and pregnancy rates in ART cycles. 
Experimental
We designed a prospective randomized 
clinical trial. Our study was carried out on fifty 
four patients who were undergoing in vitro 
fertilization (IVF) and itracytoplasmic sperm 
injection (ICSI) treatment from Jannary 2002 
to Jannary 2003 in the IVF center of Yazd and 
Day hospital. 
In the primary visit, physical examination 
and sonography showed no ovarian cyst. Patients 
were divided into two groups by randomized 
allocation method and underwent two treatment 
protocols: (a) OCP+HMG+diphereline and 
(b) HMG+diphereline. In group (a) patients 
were pretreated with OCP (ethinyl estradiol 
0.03 mg and levonorgestrol 0.15 mg, Iran 
Hormon pharmacenticals) for 14 days starting 
on the first day of mensturation and then 3.75 
mg diphereline depot (IPSEN, Germany) 
was injected intramuscularly on the last day 
of OCP administration. Patients in group 
(b) received 3.75 mg dipherelin (IPSEN, 
Germany) intramuscularly on the second 
day of menstruation. In both groups, vaginal 
sonography was performed on the first day of 
menstruation and 7 and 14 days after diphereline 
injection to detect any cyst. For controlled 
ovarian hyperstimulation in both groups, HMG 
(75 IU of FSH and 75 IU of LH, organon, 
Italy) was injected intramuscularly daily that 
started on 2nd day of the next cycle. The initial 
and adjusted dosage of gonadotropins used 
were determined according to the patients’ age 
and follicular response by serial sonography. 
Follicular growth was monitored by vaginal 
sonography that started on the day 9 of cycle, 
and then, depending on the size of follicles. 
When there were at least three follicles larger 
than 18 mm in diameter shown in sonography, 
Human Chorionic Gonadotropin (HCG) (10000 
IU, Serono, Italy) was injected intramuscularly. 
Transvaginal oocyte recovery was performed 36 
hours after HCG administration. IVF or ICSI was 
done on oocytes and the embryos were evaluated 
on the day of transfer (second day of IVF or ICSI). 
The best embryos were selected for transfer and 
the remaining embryos were cryopreserved.The 
luteal phase was supplemented by 400 mg of 
micronized progestrone (cyclogest, Schering, 
Canada) which was self-administered by the 
patients, vaginally. Pregnancy was defined as 
the presence of one or more fetal hearts detected 
on sonography performed at least 4 weeks 
after embryo transfer (ET). Cycle outcome 
was quantified by the number of ovarian cyst 
(>26 mm in diameter), the number of HMG 
ampules required, number of follicles at the 
110
Ovarian Cysts Formation During Depot Formulation of GnRH-a Therapy and ...
time of HCG administration, number of oocytes 
retrieved, number of embryos, implantation rate 
and pregnancy rate. The implantation rate was 
calculated by dividing the number of fetal hearts 
visualized at the time of the first sonography by 
the number of embryos transferred and clinical 
pregnancy rate was calculated by dividing the 
number of clinical pregnancies by the number of 
patients who underwent embryo transfer.
The study was approved by Shahid Sadoughi 
University of Medical Sciences, yazd, Iran.
The data were analysed with the use of the 
Chi square test and t-test. A 95% confidence 
interval was calculated for all performed tests. 
A p value of <0.05 was considered statistically 
significant.
Results
A total of 54 IVF and intracytoplasmic sperm 
injection (ICSI) cycles were performed, Sixteen 
patients underwent the second course of IVF and 
ICSI, with intervals more than 6 months. The 
causes of infertility among our patients were as 
follows: male factor in 21 cases, tubal damage in 
20 cases, unexplained infertility in 6 cases and 
anovulation in 7 cases. The etiology and duration 
of infertility were equally distributed among the 
groups. Three patients were excluded from study 
because of incomplete data. 
There were no statistical difference in the 
ovarian response variables among the two group. 
(Table 1). No ovarian cyst formation occurred in 
either of the two groups. Differences between 
the mean number of follicles (9.2±2.1 and 
9.4±2.9), mean number of oocytes (5.0 ±2.8 and 
5.4±5.7), mean implantation rate (0.02±0.08 
and 0.03±0.10 ) and mean pregnancy rate (0.09 
and 0.11) were not statistically significant in the 
two groups.
41% of patients (22/54) were >35 years old at 
the time of the ovulation induction. The patients 
in group (a) were between 22-43 years old and 
in group (b) were between 27-42 years old. The 
mean age between two groups were significantly 
different ((a): 31.48±5.82 versus (b): 35.27± 
4.13) (p value=0.007). So we divided the patients 
into two groups based on their ages: (20-34) and 
(≥35) and then outcome of cycles were studied 
in the two age groups. The results showed no 
significant difference between two protocols in 
the gonadotropin consumption (p value=0.27), 
mean number of follicles (p value=0.76) and 
mean number of embryos (p value=0.81) based 
on their ages ( Table 2).
Discussion
This study demonstrated that with the 
use of depot formulation of GnRH-a no 
cyst formation observed in ART cycles, no 
significant differences in the number of follicles 
the number of oocytes, the implantation rate and 
the pregnancy rate between patients who had 
taken OC before dipherelin and HMG and those 
who had not taken OC. 
It was shown that the use of a GnRH-
a together with gonadotropins for ovarian 
stimulation in assisted conception results in 
significantly lower cancellation rates, increase 
in the number of oocyts obtained and increase in 
the pregnancy rate. In addition, the long protocols 
have better outcomes in comparison with short 
and ultrashort protocols. (4) Since menstrual 
cycles in women often are not exactly 28 days, 
and the stress during treatment may delay the 
variable
Protocols
Oc+diphereline+HMG diphereline +HMG P value
Cyst formation
(size>28mm) No cyst No cyst NS
Number of follicles >16mm 9.2±2.1 9.4±2.9 NS
Number of oocytes retrived 5.0±2/8 5.4±5.7 NS
Implantation rate(%) 0.02±0/08 0.03±0.10 NS
Pregnancy rate(%) 0.09±0/29 0.11±0.42 NS
Note: Data are presented as mean ± standard deviation
Table 1. Outcome of cycles in two study protocols.
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time of ovulation, the patients who undergoing 
midluteal initation of GnRH-a therapy actually 
may receive the drug in the early luteal phase, 
which may be associated with poorer outcomes 
(5-6). In addition, it may interfere with early 
pregnancy (9). So, follicular initition of GnRH-
a is recommended (10). The only disadvantage 
of follicular over midluteal initiation of GnRH-a 
administration is the possibility of an increased 
incidence of ovarian cyst formation (7). In these 
patients the period leading to ovarian suppression 
frequently is prolonged and unpredictable, 
requiring repeated blood tests and additional 
US scans. Moreover, a prolonged period of 
ovarian suppression causes additional stress and 
anxiety for the patients who are undergoing IVF 
treatment. Therefore, it would be of considerable 
interest if the occurrence of ovarian cysts could 
be eliminated without a negative effect on 
subsequent follicular development, embryo 
quality and pregnancy rate.
Functional ovarian cysts probably are formed 
by the transient initial stimulatory effect of 
GnRH-a, which stimulates primordial follicles 
to grow. Owing to rapid pituitary suppression, 
however, continued follicular development and 
ovulation dose not occur and follicular cysts are 
formed (11). The initial stimulatory effect of the 
GnRH-a increases the levels of both FSH and 
LH. However, early follicular development is 
caused primarily by FSH and therefore the surge 
of FSH rather than LH probably is responsible 
for functional cyst formation (12). Therefore, to 
abolish the formation of functional ovarian cysts 
in the follicular phase of the cycle, the initial 
FSH surge should be attenuated. 
Vizziello et al (13) studied flare-up of 
gonadotropins during treatment with triptoreline 
and confrimed that LH levels show an increase 
six-fold the basic values while FSH levels 
increases two-fold after two days of treatment. 
Sonntag et al (10) showed that serum LH and 
FSH levels were significantly lower in patients 
who received depot formulation of GnRH-a 
(triptorelin acetate) and discussed that higher 
FSH stimulation dose requirment and lower 
oocyt number and fertilization rate indicating a 
need for minimal LH activity in folliculogenesis 
and oocyts development. 
Another study (14) showed that low dose 
of triptorelin produces more suppression on 
endogenous LH in pituitary than buserelin long 
protocols. Dalprato, et al reported that low 
doses of short GnRH-a requiring lower amount 
of gonadotropins in comparison with depot 
formulations (15). Given the results of these 
studies it seems that depot formulation of GnRH-
a cause deeper pituitary suppression.
Our data confirm that with administration of 
depot formulation of GnRH-a ovarian cyst was 
not increased. It can be due to the more decrease 
in FSH level in comparison with LH levels in 
flare up. So, in patients with the history of 
ovarian cyst with GnRH-a adminstration in the 
previous cycles depot formulation of GnRH-a 
can be considered.
In an attempt to program IVF cycles and 
abolish the occurrence of a premature LH surge, 
Templeton et al (16) studied the effects of 
norethindrone and a combined OC on pituitary 
suppression. They reported a significantly 
slower response to combined treatment with 
















20-34 13          28.92±4.13 11±5.98 2.76±1.78 16 33.11±8.23 10.40±4.30 3.75±1.94
≥35 16 30.81±6.17 8.18±7.41 2.12±1.92 6 39.57±11.92 6.50±3.44 2.83±2.04
total 29 33.56±9.10 9.44±6.84 2.41±1.86 22 31.30±6.99 9.28±4.38 3.50±1.97
Note: Data are presented as mean±standard deviation
a (p value=0.27) 
b (p value=0.76)
c (p value=0.81)
Table 2. Comparing mean number of HMG, follicles and embryo between the two study protocols based on age.
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clomiphene citrate and HMG in patients who 
were pretreated with OC. They suggested that 
OCs cause a deeper pituitary suppression.
In another study, Forman et al (17) reported 
a similar level of suppression of LH, but a 
significantly deeper suppression of FSH with the 
OC compared with norethisterone.
Combination of depot GnRH-a and OC 
in our study did not show any difference in 
comparison with depot formulation alone. This 
can be because OC has negligible effect as 
compared with depot formulation of GnRH-
a on pituitary supression. Due to this fact no 
significant differences in growth of follicles, 
number of oocyt and embyo, implantation rates 
and pregnancy in patients who had received OC 
and depot form of GnRH-a, in comparison with 
the patients who received depot formulation of 
GnRH-a alone were found.
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